$BCTX
BriaCell Therapeutics Corp.

2022 Q4 Form 10-Q Financial Statement

#000149315222035452 Filed on December 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2021 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.148M $1.409M
YoY Change 52.43% 509.21%
% of Gross Profit
Research & Development $3.255M $875.6K
YoY Change 271.75% 487.44%
% of Gross Profit
Depreciation & Amortization $3.818K $3.820K
YoY Change -0.05% 0.26%
% of Gross Profit
Operating Expenses $5.403M $2.285M
YoY Change 136.48% 500.67%
Operating Profit -$5.403M -$2.285M
YoY Change 136.48%
Interest Expense $5.360K
YoY Change -134.1%
% of Operating Profit
Other Income/Expense, Net $4.297M -$106.8K
YoY Change -4124.17%
Pretax Income -$1.107M -$2.386M
YoY Change -53.63% 466.35%
Income Tax
% Of Pretax Income
Net Earnings -$1.107M -$2.386M
YoY Change -53.63% 466.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$1.81
Diluted Earnings Per Share -$71.31K -$156.6K
COMMON SHARES
Basic Shares Outstanding 15.52M shares 15.24M shares
Diluted Shares Outstanding 15.52M shares

Balance Sheet

Concept 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.45M $55.49M
YoY Change -32.51% 645884.75%
Cash & Equivalents $37.45M $55.49M
Short-Term Investments
Other Short-Term Assets $742.1K $406.8K
YoY Change 82.43% 50.19%
Inventory
Prepaid Expenses $742.1K
Receivables $29.70K $19.33K
Other Receivables $0.00 $0.00
Total Short-Term Assets $38.22M $55.92M
YoY Change -31.64% 19344.38%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.00 $0.00
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $226.5K $241.8K
YoY Change -6.32% -23.43%
TOTAL ASSETS
Total Short-Term Assets $38.22M $55.92M
Total Long-Term Assets $226.5K $241.8K
Total Assets $38.45M $56.16M
YoY Change -31.53% 9207.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $791.8K $240.1K
YoY Change 229.83% -94.73%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $974.1K $431.4K
YoY Change 125.8% -91.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $26.96K
YoY Change -100.0% -85.98%
Other Long-Term Liabilities $27.14M $306.2K
YoY Change 8763.54%
Total Long-Term Liabilities $27.14M $333.2K
YoY Change 8046.33% 73.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $974.1K $431.4K
Total Long-Term Liabilities $27.14M $333.2K
Total Liabilities $28.12M $764.6K
YoY Change 3577.46% -84.99%
SHAREHOLDERS EQUITY
Retained Earnings -$61.46M
YoY Change
Common Stock $71.93M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.33M $55.39M
YoY Change
Total Liabilities & Shareholders Equity $38.45M $56.16M
YoY Change -31.53% 9207.54%

Cashflow Statement

Concept 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$1.107M -$2.386M
YoY Change -53.63% 466.35%
Depreciation, Depletion And Amortization $3.818K $3.820K
YoY Change -0.05% 0.26%
Cash From Operating Activities -$3.542M -$1.779M
YoY Change 99.17% 2961.27%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$47.29K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$3.542M -1.779M
Cash From Investing Activities
Cash From Financing Activities -$47.29K 0.000
Net Change In Cash -$3.590M -1.779M
YoY Change 101.83% 5637.42%
FREE CASH FLOW
Cash From Operating Activities -$3.542M -$1.779M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001610820
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Interest Expense
InterestExpense
usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
usd
CY2021Q4 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
usd
CY2021Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2022Q4 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-10-31
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
001-40101
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
BRIACELL THERAPEUTICS CORP.
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
2 usd
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1099599
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
235 15th Street, Suite 300,
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
West Vancouver
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V7T 2X1
CY2022Q4 dei City Area Code
CityAreaCode
604
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
921-1810
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q4 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q4 dei Entity Shell Company
EntityShellCompany
true
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15518018 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37451976 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41041652 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29698 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24103 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
742123 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1280945 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38223797 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
42346700 usd
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
2 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
226521 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
230339 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
226523 usd
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
230341 usd
CY2022Q4 us-gaap Assets
Assets
38450320 usd
CY2022Q3 us-gaap Assets
Assets
42577041 usd
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
791748 usd
CY2022Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
463280 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
182302 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
477807 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
974050 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
941087 usd
CY2022Q4 BCTX Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
27141938 usd
CY2022Q3 BCTX Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
31307022 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
27141938 usd
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
31307022 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15518018 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15518018 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15518018 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15518018 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
65589293 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
65589293 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
6340101 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5228160 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-138684 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61456378 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60349837 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10334332 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10328932 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38450320 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42577041 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3255215 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
875636 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2147936 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1409173 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
5403151 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
2284809 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5403151 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2284809 usd
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
188353 usd
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
6305 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
979 usd
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4117790 usd
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
25254036 usd
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9533 usd
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
34 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4296610 usd
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25248676 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1106541 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-27533485 usd
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15518018 shares
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15238646 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
10328932 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1111941 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1106541 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10334332 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
27671721 usd
CY2021Q4 BCTX Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
927407 usd
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
518134 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-27533485 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1583777 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1106541 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-27533485 usd
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3818 usd
CY2021Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3817 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
1111941 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
518134 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
979 usd
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4117790 usd
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
25254036 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5595 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6755 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-538822 usd
CY2021Q4 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-110105 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
328468 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
29334 usd
CY2022Q4 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-295505 usd
CY2021Q4 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-154763 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3542382 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1778599 usd
CY2022Q4 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
47294 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-47294 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3589676 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1778599 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41041652 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57268685 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37451976 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55490086 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61456378 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3542382 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
37451976 usd
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
41041652 usd
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
27141938 usd
CY2022Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
31307022 usd
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Share Price
SharePrice
5.50
CY2022Q3 us-gaap Share Price
SharePrice
6.50
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1 pure
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0423 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0268 pure
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1670400 shares
CY2022Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1373053 shares
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
1111941 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
518134 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1106541 usd
CY2021Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27533485 usd
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15518018 shares
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15238646 shares
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81

Files In Submission

Name View Source Status
0001493152-22-035452-index-headers.html Edgar Link pending
0001493152-22-035452-index.html Edgar Link pending
0001493152-22-035452.txt Edgar Link pending
0001493152-22-035452-xbrl.zip Edgar Link pending
bctx-20221031.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bctx-20221031_def.xml Edgar Link unprocessable
bctx-20221031_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
bctx-20221031_lab.xml Edgar Link unprocessable
bctx-20221031_cal.xml Edgar Link unprocessable